These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 27404978)

  • 41. Evaluation of a risk-guided strategy for empirical carbapenem use in febrile neutropenia.
    Khoo AL; Zhao YJ; Teng M; Ying D; Jin J; Chee YL; Poon LM; Lim SE; Koh LP; Chng WJ; Lim BP; Hsu LY; Chai LYA
    Int J Antimicrob Agents; 2018 Sep; 52(3):350-357. PubMed ID: 29751120
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Editorial commentary: imminent challenges: carbapenem-resistant enterobacteriaceae in transplant recipients and patients with hematologic malignancy.
    Johnson K; Boucher HW
    Clin Infect Dis; 2014 May; 58(9):1284-6. PubMed ID: 24463279
    [No Abstract]   [Full Text] [Related]  

  • 43. Frequency of and risk factors for carbapenem-resistant
    Barber KE; Wagner JL; Larry RC; Stover KR
    J Med Microbiol; 2021 Feb; 70(2):. PubMed ID: 33263511
    [No Abstract]   [Full Text] [Related]  

  • 44. Pseudomonas aeruginosa bloodstream infections in children and adolescents: risk factors associated with carbapenem resistance and mortality.
    Rodríguez NEG; Aguilera-Alonso D; Escosa L; Gómez-Gil MR; Manzanares Á; Ascaso MG; Bermejo-Gómez A; Abad MJG; Ramos AM; Núñez AS; Orellana MÁ; Cercenado E; Lozano JS; Calvo C; Baquero-Artigao F;
    J Hosp Infect; 2024 Jul; 149():56-64. PubMed ID: 38735628
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Impact of Modifying Empirical Antibiotic Therapy Based on Intestinal Colonization Status on Clinical Outcomes of Febrile Neutropenic Patients.
    Alrstom A; Alsuliman T; Daher N; Abouharb R
    Infect Chemother; 2021 Mar; 53(1):63-74. PubMed ID: 33538132
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fecal carriage of carbapenem-resistant Enterobacteriaceae in a Chinese university hospital.
    Zhao ZC; Xu XH; Liu MB; Wu J; Lin J; Li B
    Am J Infect Control; 2014 May; 42(5):e61-4. PubMed ID: 24773806
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genetic Characterization of Carbapenem-Resistant Enterobacteriaceae and the Spread of Carbapenem-Resistant Klebsiella pneumonia ST340 at a University Hospital in Thailand.
    Netikul T; Kiratisin P
    PLoS One; 2015; 10(9):e0139116. PubMed ID: 26407326
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The impact of colistin-based regimens on mortality compared to other antimicrobials in patients with carbapenem-resistant Enterobacterales bacteremia in South African hospitals: a cross-sectional study.
    Ngoma N; Perovic O; de Voux A; Musekiwa A; Shuping L;
    BMC Infect Dis; 2024 Jun; 24(1):561. PubMed ID: 38840122
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk Factors for Carbapenem-Resistant
    Rebold N; Lagnf AM; Alosaimy S; Holger DJ; Witucki P; Mannino A; Dierker M; Lucas K; Kunz Coyne AJ; El Ghali A; Caniff KE; Veve MP; Rybak MJ
    Microbiol Spectr; 2023 Feb; 11(1):e0264722. PubMed ID: 36622246
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bloodstream infections in neutropenic and non-neutropenic patients with haematological malignancies: epidemiological trends and clinical outcomes in Queensland, Australia over the last 20 years.
    Peri AM; Edwards F; Henden A; Harris PNA; Chatfield MD; Paterson DL; Laupland KB
    Clin Exp Med; 2023 Dec; 23(8):4563-4573. PubMed ID: 37815735
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Asymptomatic rectal carriage of blaKPC producing carbapenem-resistant Enterobacteriaceae: who is prone to become clinically infected?
    Schechner V; Kotlovsky T; Kazma M; Mishali H; Schwartz D; Navon-Venezia S; Schwaber MJ; Carmeli Y
    Clin Microbiol Infect; 2013 May; 19(5):451-6. PubMed ID: 22563800
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The carbapenem-resistant Enterobacteriaceae score: a bedside score to rule out infection with carbapenem-resistant Enterobacteriaceae among hospitalized patients.
    Martin ET; Tansek R; Collins V; Hayakawa K; Abreu-Lanfranco O; Chopra T; Lephart PR; Pogue JM; Kaye KS; Marchaim D
    Am J Infect Control; 2013 Feb; 41(2):180-2. PubMed ID: 22939417
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical efficacy of β-lactam/β-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum β-lactamase-producing Enterobacteriaceae in haematological patients with neutropaenia: a study protocol for a retrospective observational study (BICAR).
    Gudiol C; Royo-Cebrecos C; Tebe C; Abdala E; Akova M; Álvarez R; Maestro-de la Calle G; Cano A; Cervera C; Clemente WT; Martín-Dávila P; Freifeld A; Gómez L; Gottlieb T; Gurguí M; Herrera F; Manzur A; Maschmeyer G; Meije Y; Montejo M; Peghin M; Rodríguez-Baño J; Ruiz-Camps I; Sukiennik TC; Carratalà J;
    BMJ Open; 2017 Jan; 7(1):e013268. PubMed ID: 28115333
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Global prevalence of carbapenem resistance in neutropenic patients and association with mortality and carbapenem use: systematic review and meta-analysis.
    Righi E; Peri AM; Harris PN; Wailan AM; Liborio M; Lane SW; Paterson DL
    J Antimicrob Chemother; 2017 Mar; 72(3):668-677. PubMed ID: 27999023
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Carbapenem-resistant Enterobacteriaceae in special populations: Solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies.
    Pouch SM; Satlin MJ
    Virulence; 2017 May; 8(4):391-402. PubMed ID: 27470662
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rate of colonization of health care workers by carbapenem-resistant Enterobacteriaceae in an endemic hospital: A prospective study.
    Bitterman R; Geffen Y; Rabino G; Eluk O; Warman S; Greenblatt AS; Neuberger A; Reisner SA; Hussein K; Paul M
    Am J Infect Control; 2016 Sep; 44(9):1053-4. PubMed ID: 27125914
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk Factors for Recurrence of Carbapenem-Resistant Enterobacteriaceae Carriage: Case-Control Study.
    Bart Y; Paul M; Eluk O; Geffen Y; Rabino G; Hussein K
    Infect Control Hosp Epidemiol; 2015 Aug; 36(8):936-41. PubMed ID: 25869912
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections.
    Ku K; Pogue JM; Moshos J; Bheemreddy S; Wang Y; Bhargava A; Campbell M; Khandker N; Lephart PR; Chopra T; Hayakawa K; Martin ET; Abreu-Lanfranco O; Dhar S; Kaye KS; Marchaim D
    Am J Infect Control; 2012 Dec; 40(10):983-7. PubMed ID: 22440526
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adding double carbapenem therapy to the armamentarium against carbapenem-resistant Enterobacteriaceae bloodstream infections.
    White BP; Patel S; Tsui J; Chastain DB
    Infect Dis (Lond); 2019 Mar; 51(3):161-167. PubMed ID: 30663923
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Factors Associated to Prevalence and Incidence of Carbapenem-Resistant Enterobacteriaceae Fecal Carriage: A Cohort Study in a Mexican Tertiary Care Hospital.
    Torres-Gonzalez P; Cervera-Hernandez ME; Niembro-Ortega MD; Leal-Vega F; Cruz-Hervert LP; García-García L; Galindo-Fraga A; Martinez-Gamboa A; Bobadilla-Del Valle M; Sifuentes-Osornio J; Ponce-de-Leon A
    PLoS One; 2015; 10(10):e0139883. PubMed ID: 26431402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.